← Back to Search

Nonsteroidal Anti-inflammatory Drug

Randomized to USPSTF Criteria for Prophylaxis of Preeclampsia

Phase 4
Waitlist Available
Led By Sebastian Z Ramos, MD
Research Sponsored by Women and Infants Hospital of Rhode Island
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this will be measured from 24 weeks until 39 weeks.
Awards & highlights

Study Summary

This study is evaluating whether aspirin may be more effective when given to all pregnant women, rather than only those at high risk.

Eligible Conditions
  • Prophylaxis of Preeclampsia
  • Medication Adherence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this will be measured from 24 weeks until 39 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and this will be measured from 24 weeks until 39 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence to aspirin use
Secondary outcome measures
Fetal growth restriction
Placental abruption
Rates of postpartum hemorrhage
+1 more

Trial Design

2Treatment groups
Active Control
Group I: Randomized to USPSTF CriteriaActive Control1 Intervention
Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
Group II: Randomized to Universal aspirin receiptActive Control1 Intervention
Women randomized to receiving low dose aspirin without knowing their risk status.

Find a Location

Who is running the clinical trial?

Women and Infants Hospital of Rhode IslandLead Sponsor
109 Previous Clinical Trials
38,444 Total Patients Enrolled
Sebastian Z Ramos, MDPrincipal InvestigatorWomen and Infants Hospital
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Annals of Internal MedicineJournal
Low-dose Aspirin for Prevention of Morbidity and Mortality from Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force
Henderson, Jillian T., Evelyn P. Whitlock, Elizabeth O’Connor, Caitlyn A. Senger, Jamie H. Thompson, and Maya G. Rowland. 2014. “Low-dose Aspirin for Prevention of Morbidity and Mortality from Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force”. Annals of Internal Medicine. American College of Physicians. doi:10.7326/m13-2844.
clinicaltrials.govStudy
Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
Sebastian Ramos 2021. "Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04797949.
All > Preeclampsia > Durlaza
~38 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top